Endovastec(SH:688016) Xin Lang Cai Jing·2025-09-23 03:34Core Viewpoint - The stock of Xinmai Medical has experienced a decline of 3.81% year-to-date, with a notable drop of 10.95% over the past 20 trading days, indicating potential challenges in the company's performance and market perception [1]. Company Overview - Xinmai Medical, officially known as Shanghai MicroPort CardioFlow MedTech Co., Ltd., was established on August 17, 2012, and went public on July 22, 2019. The company specializes in the research, development, production, and sales of interventional medical devices for aortic and peripheral blood vessels [1]. - The company's revenue composition is primarily from aortic products (71.94%), followed by peripheral and other products (28.04%), with a negligible contribution from other sources (0.02%) [1]. Financial Performance - For the first half of 2025, Xinmai Medical reported a revenue of 714 million yuan, reflecting a year-on-year decrease of 9.24%. The net profit attributable to shareholders was 315 million yuan, down 22.03% compared to the previous year [2]. - Since its A-share listing, Xinmai Medical has distributed a total of 922 million yuan in dividends, with 660 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Xinmai Medical was 17,500, a decrease of 3.61% from the previous period. The average number of tradable shares per shareholder increased by 3.75% to 7,035 shares [2]. - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and Hong Kong Central Clearing Limited, with increases in holdings compared to the previous period [3].